GSK2132231A Antigen-Specific Cancer Immunotherapeutic as First-line Treatment of Patients With Unresectable Metastatic Melanoma

Trial Profile

GSK2132231A Antigen-Specific Cancer Immunotherapeutic as First-line Treatment of Patients With Unresectable Metastatic Melanoma

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Aug 2015

At a glance

  • Drugs Zastumotide (Primary) ; AS15
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms PREDICT
  • Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals
  • Most Recent Events

    • 21 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 11 Dec 2014 Planned End Date changed from 1 Jun 2016 to 1 Feb 2015, according to the ClinicalTrials.gov record.
    • 10 Aug 2012 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top